WallStreetZenWallStreetZen

NASDAQ: TRAX
First Tracks Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TRAX

Based on 7 analysts offering 12 month price targets for First Tracks Biotherapeutics Inc

Min Forecast
$30.00+76.16%
Avg Forecast
$39.43+131.53%
Max Forecast
$54.00+217.09%

Should I buy or sell TRAX stock?

Based on 7 analysts offering ratings for First Tracks Biotherapeutics Inc.

Strong Buy
Strong Buy
5 analysts 71.43%
Buy
2 analysts 28.57%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TRAX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates TRAX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their TRAX stock forecasts and price targets.

TRAX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-08
lockedlocked$00.00+00.00%2026-05-04
lockedlocked$00.00+00.00%2026-04-28
lockedlocked$00.00+00.00%2026-04-24
lockedlocked$00.00+00.00%2026-04-23
Barclays
Top 3%
98
Strong BuyInitiates Coverage On$40.00+134.88%2026-04-22
UBS
Top 17%
84
Strong BuyInitiates Coverage On$45.00+164.24%2026-04-21

1 of 1

Forecast return on equity

Is TRAX forecast to generate an efficient return?

Company
-54.26%
Industry
95.98%
Market
169.41%
TRAX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TRAX forecast to generate an efficient return on assets?

Company
-48.07%
Industry
28.3%
TRAX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TRAX earnings per share forecast

What is TRAX's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$3.76
Avg 2 year Forecast
-$3.40
Avg 3 year Forecast
-$3.46

TRAX revenue forecast

What is TRAX's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

TRAX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRAX$17.03$39.43+131.53%Strong Buy
RIGL$32.08$69.00+115.09%Strong Buy
BBOT$7.46$24.75+231.77%Strong Buy
CADL$8.16$25.50+212.50%Strong Buy
GYRE$6.06N/AN/A
View Top Biotech Stocks

First Tracks Biotherapeutics Stock Forecast FAQ

Is First Tracks Biotherapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: TRAX) stock is to Strong Buy TRAX stock.

Out of 7 analysts, 5 (71.43%) are recommending TRAX as a Strong Buy, 2 (28.57%) are recommending TRAX as a Buy, 0 (0%) are recommending TRAX as a Hold, 0 (0%) are recommending TRAX as a Sell, and 0 (0%) are recommending TRAX as a Strong Sell.

If you're new to stock investing, here's how to buy First Tracks Biotherapeutics stock.

What is TRAX's earnings growth forecast for 2026-2028?

(NASDAQ: TRAX) First Tracks Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.99%.

First Tracks Biotherapeutics's earnings in 2026 is N/A.On average, 8 Wall Street analysts forecast TRAX's earnings for 2026 to be -$131,362,836, with the lowest TRAX earnings forecast at -$142,420,232, and the highest TRAX earnings forecast at -$123,100,320. On average, 8 Wall Street analysts forecast TRAX's earnings for 2027 to be -$118,693,412, with the lowest TRAX earnings forecast at -$141,223,423, and the highest TRAX earnings forecast at -$83,532,360.

In 2028, TRAX is forecast to generate -$120,888,143 in earnings, with the lowest earnings forecast at -$155,585,127 and the highest earnings forecast at -$80,967,770.

What is TRAX's revenue growth forecast for 2026-2028?

(NASDAQ: TRAX) First Tracks Biotherapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.81%.

First Tracks Biotherapeutics's revenue in 2026 is N/A.On average, 8 Wall Street analysts forecast TRAX's revenue for 2026 to be $0, with the lowest TRAX revenue forecast at $0, and the highest TRAX revenue forecast at $0. On average, 8 Wall Street analysts forecast TRAX's revenue for 2027 to be $0, with the lowest TRAX revenue forecast at $0, and the highest TRAX revenue forecast at $0.

In 2028, TRAX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is TRAX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: TRAX) forecast ROA is -48.07%, which is lower than the forecast US Biotechnology industry average of 28.3%.

What is TRAX's Price Target?

According to 7 Wall Street analysts that have issued a 1 year TRAX price target, the average TRAX price target is $39.43, with the highest TRAX stock price forecast at $54.00 and the lowest TRAX stock price forecast at $30.00.

On average, Wall Street analysts predict that First Tracks Biotherapeutics's share price could reach $39.43 by Jun 8, 2027. The average First Tracks Biotherapeutics stock price prediction forecasts a potential upside of 131.53% from the current TRAX share price of $17.03.

What is TRAX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: TRAX) First Tracks Biotherapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that TRAX's EPS will be -$3.76 for 2026, with the lowest EPS forecast at -$4.08, and the highest EPS forecast at -$3.53. On average, analysts forecast that TRAX's EPS will be -$3.40 for 2027, with the lowest EPS forecast at -$4.05, and the highest EPS forecast at -$2.39. In 2028, TRAX's EPS is forecast to hit -$3.46 (min: -$4.46, max: -$2.32).

What is TRAX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: TRAX) forecast ROE is -54.26%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.